Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis

Stephanie Hennig; Joseph Stanning; Christine Staatz; Alison Thomson

doi:10.1007/s40262-013-0036-y

Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis

Stephanie Hennig
, Joseph Stanning
, Christine Staatz
, Alison Thomson

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

69 Citations (Scopus)

Abstract

While several studies have examined the pharmacokinetics of tobramycin in patients with cystic fibrosis (CF), there is no consensus on whether they differ in patients with and without CF. The objectives of this study were to identify covariates which explain pharmacokinetic variability and to examine whether having the disease CF in itself alters these relationships and drug dose requirements.

Original language	English
Pages (from-to)	289-301
Number of pages	13
Journal	Clinical Pharmacokinetics
Volume	52
Issue number	4
DOIs	https://doi.org/10.1007/s40262-013-0036-y
Publication status	Published - 1 Apr 2013

Keywords

tobramycin
cystic fibrosis
pharmacokinetics
pharmacometrics
patients

Access to Document

10.1007/s40262-013-0036-y

Cite this

@article{2d9194e8289c4faa8272211a70e81932,

title = "Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis",

abstract = "While several studies have examined the pharmacokinetics of tobramycin in patients with cystic fibrosis (CF), there is no consensus on whether they differ in patients with and without CF. The objectives of this study were to identify covariates which explain pharmacokinetic variability and to examine whether having the disease CF in itself alters these relationships and drug dose requirements.",

keywords = "tobramycin, cystic fibrosis, pharmacokinetics, pharmacometrics, patients",

author = "Stephanie Hennig and Joseph Stanning and Christine Staatz and Alison Thomson",

year = "2013",

month = apr,

day = "1",

doi = "10.1007/s40262-013-0036-y",

language = "English",

volume = "52",

pages = "289--301",

journal = "Clinical Pharmacokinetics ",

issn = "0312-5963",

publisher = "Adis",

number = "4",

}

TY - JOUR

T1 - Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis

AU - Hennig, Stephanie

AU - Stanning, Joseph

AU - Staatz, Christine

AU - Thomson, Alison

PY - 2013/4/1

Y1 - 2013/4/1

N2 - While several studies have examined the pharmacokinetics of tobramycin in patients with cystic fibrosis (CF), there is no consensus on whether they differ in patients with and without CF. The objectives of this study were to identify covariates which explain pharmacokinetic variability and to examine whether having the disease CF in itself alters these relationships and drug dose requirements.

AB - While several studies have examined the pharmacokinetics of tobramycin in patients with cystic fibrosis (CF), there is no consensus on whether they differ in patients with and without CF. The objectives of this study were to identify covariates which explain pharmacokinetic variability and to examine whether having the disease CF in itself alters these relationships and drug dose requirements.

KW - tobramycin

KW - cystic fibrosis

KW - pharmacokinetics

KW - pharmacometrics

KW - patients

U2 - 10.1007/s40262-013-0036-y

DO - 10.1007/s40262-013-0036-y

M3 - Article

SN - 0312-5963

VL - 52

SP - 289

EP - 301

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

IS - 4

ER -

Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis

Abstract

Keywords

Access to Document

Fingerprint

Cite this